For instance, in breast cancer, the FDA-approved CDK4/6 inhibitors, such as palbociclib (Lee et al., 2022), have demonstrated substantial clinical benefits by inhibiting the activity of CCND1-CDK4 complex and arresting tumor growth. Here, CDK4 is linked to neoplasm.